MedTrace Logo

Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain

NCT03697720 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-10-18

Study results available
· View outcomes & findings →

Summary

The goal of this study is to see if optimized use of naproxen for treatment of dysmenorrhea will improve pain report from baseline. In addition, we will determine whether cross-organ influences from the uterus on bladder pain sensitivity change from baseline after reduced menstrual pain experience over six months. Finally, a battery of quantitative sensory tests and EEG measures of sensory sensitivity will be used to evaluate mechanisms associated with improvements in menstrual and bladder pain.

Conditions

Interventions

DRUG

Naproxen

Participants will take naproxen 500mg BID before and for the first 3 days of their period.

Sponsors & Collaborators

  • Endeavor Health

    lead OTHER

Principal Investigators

  • Frank Tu, MD, MPH · Endeavor Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-09
Primary Completion
2020-11-23
Completion
2023-09-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697720 on ClinicalTrials.gov